Search the Newsreel

GeneDx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against GeneDx Holdings Corp. - WGS

ClaimsFiler is reminding investors who suffered losses exceeding $100,000 in GeneDx Holdings Corp. (NasdaqGS: WGS) to file as lead plaintiff in a securities class action lawsuit by August 3, 2026. The lawsuit alleges that GeneDx and its executives failed to disclose material information during …

MiMedx Group, Inc Revenue Breakdown – BOATS:MDXG

MiMedx Group, Inc. (MDXG) last year generated $418.63 million in revenue, with its top-performing segment, Wound, contributing $276.33 million. The United States was the primary geographic contributor, accounting for the entire $418.63 million in revenue last year, showing an increase from $348.88 million the …

MiMedx Group Inc (MDXG) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of MiMedx Group Inc (MDXG), noting its current valuation score of 6.65 and its position within the Biotechnology & Medical Research industry. It details the company's current P/E ratio, comparing it to historical highs and lows, while also …

CareDx Inc (CDNA) Institutional Confidence

CareDx Inc (CDNA) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 101.54%, despite an 11.87% decrease quarter-over-quarter. Ron Baron is the largest institutional shareholder, holding 2.61 million shares, which …

WGS DEADLINE ALERT: GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit- August 3, 2026 Deadline

Hagens Berman is actively investigating a securities class action lawsuit against GeneDx Holdings (NASDAQ: WGS) and its executives. The lawsuit alleges that investors were misled about the Fabric Genomics acquisition and its synergy potential, leading to a 49% stock collapse after a disastrous Q1 …

MiMedx Group Inc (MDXG) Financial Health: Profitability & Balance Sheet Analysis

MiMedx Group Inc (MDXG) has a robust financial status with a score of 8.21, ranking highly in the Biotechnology & Medical Research industry. Despite this, its latest quarterly revenue decreased by 33.12% year-over-year, and net profit saw a 254.63% decrease. The report highlights undisclosed …

MDXG|MiMedx Group Inc|Price:4.200|Chg%:+0.070

MiMedx Group Inc. (MDXG) shows strong fundamentals and high growth potential, with its valuation assessed as fairly priced within the Biotechnology & Medical Research industry. Institutional ownership is notably high, and analysts have given it a "Buy" rating with a target price of 6.60. …

HAGENS BERMAN, SOBOL SHAPIRO LLP ALERT: GeneDx Holdings Corp. (NASDAQ: WGS) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 3, 2026 Lead Plaintiff Deadline

Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS), urging investors with significant losses to come forward. The lawsuit alleges that GeneDx misled investors about the benefits of its Fabric Genomics acquisition, concealing integration …

WGS Deadline: Rosen Law Firm Urges GeneDx Holdings Corp. (NASDAQ: WGS) Stockholders to Contact the Firm for Information About Their Rights

Rosen Law Firm is reminding investors of GeneDx Holdings Corp. (NASDAQ: WGS) about a class action lawsuit filed on behalf of stockholders who purchased common stock between April 16, 2025 and May 4, 2026. The lawsuit alleges that GeneDx misled investors about the positive …

Lost Money on GeneDx Holdings Corp. (WGS)? Join Class Action Suit Seeking Recovery - Contact SueWallSt

SueWallSt, powered by Levi & Korsinsky LLP, has filed a class action lawsuit against GeneDx Holdings Corp. (WGS) on behalf of investors who purchased securities between April 16, 2025, and May 4, 2026. This suit follows a significant 49% stock drop after GeneDx disclosed …

WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is encouraging investors of GeneDx Holdings Corp. (NASDAQ: WGS) to join a class action lawsuit alleging securities fraud. The lawsuit claims that GeneDx made false and misleading statements to the market during the period of April 16, 2025, to May …

CareDx (CDNA) Expected to Post Quarterly Earnings on Thursday

CareDx (CDNA) Earnings Expected to Grow: Should You Buy?

Is CareDx (CDNA) Fully Valued After Its Medicare Coverage Win?

CareDx (CDNA) is in focus after Medicare finalized coverage for its molecular transplant surveillance tests, leading to a significant recent surge in its stock price. While analysts and one valuation model view the stock as overvalued at $38.37 against a fair value of $27.80, …

WGS Deadline Alert: Levi & Korsinsky Reminds GeneDx Holdings Corp. (WGS) Investors of Securities Class Action Deadline on August 3, 2026

Levi & Korsinsky, LLP reminds investors of the August 3, 2026, deadline to seek lead plaintiff status in a securities class action lawsuit against GeneDx Holdings Corp. (WGS). The lawsuit alleges that GeneDx's leadership concealed crucial information about Fabric Genomics' performance, leading to a …

This company is letting a virus guide its new focus on cancer testing

CareDx Inc. is changing its strategic direction to focus on cancer testing, a move influenced by a virus. CEO John Hanna emphasizes the importance of being a market leader in their chosen fields. This new focus is highlighted by their significant $260 million acquisition …

Robbins LLP Reminds WGS Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class Action Against GeneDx Holdings Corp.

Robbins LLP has filed a class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of investors who purchased stock between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx misled investors about the positive impact of its Fabric Genomics …

GeneDx Holdings Corp. (WGS) warrants to be removed from Nasdaq listing

GeneDx Holdings Corp. is having a class of its warrants removed from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. Nasdaq certified its compliance with regulations to strike this warrant class from listing …

GeneDx Holdings Corp. (WGS) Slid as Revenue Fell Short of Expectations

Fred Alger Management, an investment management company, released its "Alger Small Cap Focus Fund" second-quarter 2026 investor letter. A copy of the letter can be downloaded here. U.S. equities experienced a strong recovery in Q2 2026, with the S&P 500 Index gaining 15.2%, marking …

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GeneDx Holdings Corp. of Class Action Lawsuit and Upcoming Deadlines – WGS

NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, …

EDX Medical launches bowel cancer testing service

WGS Shareholder Alert: GeneDx Holdings Corp. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

The Gross Law Firm has issued a shareholder alert regarding a securities class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS). The lawsuit alleges that GeneDx made false and misleading statements concerning the viability of its Fabric acquisition, which negatively impacted the company's financials …

MiMedx Group, Inc (MDXG) Investor Outlook: Exploring a 52.42% Potential Upside Amidst Biotech Innovations

MiMedx Group, Inc. (MDXG) offers a potential 52.42% upside for investors, driven by its specialization in placental tissue allografts and innovative healthcare solutions. Despite a reported revenue growth rate of -33.10%, the company boasts a strong return on equity and free cash flow. Analysts …

ETFs Investing in GeneDx Holdings Corp. Class A Stocks

This article lists various Exchange Traded Funds (ETFs) that hold GeneDx Holdings Corp. Class A stocks. It provides a table detailing each fund's market value, weight of GeneDx in its portfolio, issuer, management style, expense ratio, assets under management (AUM), price, change percentage, relative …

CareDx Inc (CDNA) Shares Fall 3.4% -- GF Value Says Still Overva

CareDx Inc (CDNA) shares dropped 3.4% to $38.37, yet its GF Value™ indicates the stock is significantly overvalued by 79.8%. Despite a GF Score™ of 66/100 suggesting above-average long-term potential, its valuation rank is low (1/10) and insiders have sold $8.3 million worth of …

CareDx (CDNA) Q1 2026 earnings summary

CareDx reported strong Q1 2026 results with a 39% year-over-year revenue increase to $118 million and a net income of $3 million. The company strategically divested its Lab Products business for $170 million and acquired Naveris/Navoris to enhance its focus on precision medicine and …

CareDx (CDNA) Proxy filing Summary

CareDx (CDNA) has released a proxy filing summary detailing voting matters and executive compensation. Stockholders are asked to approve the compensation of named executive officers for 2025, which includes a cash bonus program based on Revenue, Adjusted EBITDA, and Cash. The summary also clarifies …

WGS Shareholder Alert: GeneDx Holdings Corp. Securities Accessibility: Skip TopNav Consumer Products and Services News Automobiles and Parts News Food & Beverage News Home Goods & Construction News Leisure Goods News Media & Entertainment News Personal Care News Retail News Travel and Leisure News Energy News Alternative Energy News Oil Gas and Coal News Chemicals News Banks & Financial Services News Banking News Closed-End Investments News Finance and Credit Services News Investment Banking and Brokerage Services News Insurance News Real Estate & REITs News Healthcare News Healthcare Provider

Levi & Korsinsky, LLP has issued a shareholder alert for GeneDx Holdings Corp. (NASDAQ: WGS) investors, announcing a class action lawsuit for those who purchased securities between April 16, 2025, and May 4, 2026. The lawsuit stems from a significant drop in WGS shares …

HBSS Investigates Claims Against GeneDx Holdings (WGS) in Securities Class Action Suit Following Massive Impairment Charge

SAN FRANCISCO, July 20, 2026 (GLOBE NEWSWIRE) -- Hagens Berman (HBSS), a national leader in securities litigation, is actively investigating claims in a securities class action lawsuit against GeneDx Holdings (NASDAQ: WGS) and its executives, alleging defendants misled investors about the Fabric Genomics acquisition …

MIMEDX will review second-quarter results in a July 29 webcast

MiMedx (Nasdaq: MDXG) announced it will release its second-quarter 2026 operating and financial results after market close on Wednesday, July 29, 2026. The company will host a webcast and conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. …

MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29

MiMedx Group, Inc. (Nasdaq: MDXG) announced it will report its Q2 2026 operating and financial results after market close on July 29, 2026. The company's senior management will host a webcast and conference call at 4:30 p.m. Eastern Time on the same day to …

CareDx (CDNA) Is Up 39.4% After Final Medicare Coverage Clarifies Transplant Test Reimbursement Limits

CareDx (CDNA) saw its stock rise by 39.4% after securing a final Medicare Local Coverage Determination. This decision clarifies reimbursement and test frequencies for its AlloSure and AlloMap transplant surveillance tests, reducing uncertainty and aligning with clinical patterns. This improved visibility impacts CareDx's investment …

WGS Deadline: WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit

The Rosen Law Firm is reminding investors who purchased GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025, and May 4, 2026, of the August 3, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that GeneDx made misleading …

Caredx Inc (CDNA) News, Articles, Events & Latest Updates

This page compiles recent news and updates for CareDx Inc. (CDNA), a precision medicine diagnostics company. Key announcements include the finalization of Medicare coverage for its transplant tests, the acquisition of Naveris to expand into oncology, and the sale of its Lab Products business. …

CareDx (CDNA) director sells 28,779 shares and exercises options

CareDx, Inc. director Hannah Valantine reported selling 28,779 shares of common stock at a weighted average price of $36.1445 per share and exercising options for the same number of shares with exercise prices ranging from $7.96 to $20.56. These transactions, which occurred on July …

[Form 4] CareDx, Inc. Insider Trading Activity

CareDx, Inc. President and CEO, Hanna John Walter JR, reported insider trading activity on July 16, 2026. He exercised 118,000 employee stock options at $8.20 per share and subsequently sold 118,000 common shares in two transactions at weighted average prices of $36.1141 and $39.0137, …